ARCHIVES

Breast Cancer Incidence Reduced 45% In Tamoxifen Arm Of BCPT; Trial Unblinded

This article is from The Cancer Letter archive.

Vol. 24 No. 14 | April 10, 1998

Download PDF Visit The Full Archive

Related Articles

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

September 26, 2014

NCI Has Congressional Mandate Fr Planning Clinical Trials of Unconventional Therapies, Chabner Says

June 5, 1992

Obama Signs Bill Giving FDA Authority Over Tobacco Products

June 26, 2009

Feinstein Introduces New Cancer Act; Groups Say Bill Flawed

March 15, 2002

Rep. Wyden Questions NCI Motive For Choosing Not To Pursue RU 486

September 4, 1992

In Brief: Goldman Named Director, Albert Einstein Cancer Center; Wiernik Resumes Post

October 20, 1995